Zila selects Dentaid to distribute oral cancer drug
ViziLite Plus with TBlue is now available to 55% of the people in the western and eastern EU-member countries, said Zila. Zila has previously announced that it had
Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.